According to the FDA and as described on their website at FDA.gov, “There is a significant interest in the development of therapies and other consumer products derived from cannabis and its components, including cannabidiol (CBD).  The FDA recognizes the potential opportunities cannabis or cannabis-derived compounds may offer and acknowledges the significant interest in these possibilities.”

To-date, they have only officially approved Epidiolex, which contains a purified form of the drug substance CBD for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.

More studies are needed before the many potential benefits of CBD can be fully endorsed by the FDA.  With the passing of the 2018 Farm Bill the regulated production of hemp was legalized, providing the opportunity for hemp-derived CBD products to be widely produced and available to the public. It often takes many years for studies to be completed and we look forward to being able to reference additional research that confirms CBD’s potential medical benefits as it becomes available.